Nab-paclitaxel + Epirubicin

Phase 2Small molecule

HHebei Medical University Fourth Hospital

Nab-paclitaxel + Epirubicin is one of 97 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Breast CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Trodelvy

Gilead

Preclinical

37 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Nab-paclitaxel + Epirubicin

HHebei Medical University Fourth Hospital

Phase 2

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT03964753

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT04138719

Q3 2028

Phase 2Recruiting

Triple-Negative Breast Cancer

NCT04159142

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT03964753·202 enrolled

Triple-Negative Breast Cancer1 trial

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT04159142·414 enrolled

Breast Cancer1 trial

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Recruiting·HHebei Medical University Fourth Hospital·Phase 2·NCT04138719·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nab-paclitaxel + Epirubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nab-paclitaxel + Epirubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nab-paclitaxel + Epirubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Medical University Fourth Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHebei Medical University Fourth Hospital

Nab-paclitaxel + Epirubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q3 2028

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Triple-Negative Breast Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News